Previous 10 | Next 10 |
home / stock / nvmdf / nvmdf news
Novamind (OTCPK:NVMDF): FQ1 GAAP EPS of -$0.07. Revenue of $1.86M (+113% Y/Y) Press Release Total working capital of $6.83M to fund operations. For further details see: Novamind reports FQ1 results
Multistate expansion underway, signed LOI to acquire Arizona-based mental health practice Total revenue of $1,857,750, +113% when compared to same period last year Total working capital of $6,834,011 to fund operations TORONTO, ON / ACCESSWIRE / November 29, 2021 / Novamin...
TORONTO, ON / ACCESSWIRE / November 24, 2021 / Novamind Inc. (CSE:NM)(OTCQB:NVMDF)(FSE:HN2) ("Novamind" or the "Company"), a leading mental health company specialized in psychedelic medicine, today launched a new logo and announced that the Company will unite its subsidiaries and brands un...
TORONTO, ON / ACCESSWIRE / November 16, 2021 / Novamind Inc. (CSE:NM)(OTCQB:NVMDF)(FSE:HN2) ("Novamind" or the "Company"), a leading mental health company specialized in psychedelic medicine, today announced that it has signed a Letter of Intent ("LOI") to acquire Foundations for Change ,...
TORONTO, ON / ACCESSWIRE / November 15, 2021 / Novamind Inc. (CSE:NM)(OTCQB:NVMDF)(FSE:HN2) ("Novamind" or the "Company"), a leading mental health company specialized in psychedelic medicine, will participate in Mind Medicine Australia's International Summit on Psychedelic Therapies for Me...
TORONTO, ON / ACCESSWIRE / November 12, 2021 / Novamind Inc. (CSE:NM)(OTCQB:NVMDF)(FSE:HN2) ("Novamind" or the "Company"), a leading mental health company specialized in psychedelic medicine, announced today it has leased a new clinic location in Utah (the "Wheeler Park Clinic"), and will ...
Blue Cross added to list of insurance companies covering IV ketamine treatments at Novamind TORONTO, ON / ACCESSWIRE / November 10, 2021 / Novamind Inc. (CSE:NM)(OTCQB:NVMDF)(FSE:HN2) ("Novamind" or the "Company"), a leading mental health company specialized in psychedelic medicine, is ...
TORONTO, ON / ACCESSWIRE / November 8, 2021 / Novamind Inc. (CSE:NM)(OTCQB:NVMDF)(FSE:HN2) ("Novamind" or the "Company"), a leading mental health company specialized in psychedelic medicine, announces that the Ontario Securities Commission (the " OSC ") issued a...
Novamind (OTCPK:NVMDF): FY GAAP EPS of -C$0.20. Revenue of C$6.06M Press Release For further details see: Novamind reports FY results
Industry-leading revenue, $6,069,247 in FY2021 Total working capital of $9,680,431 to fund operations Expanded network to six clinics and three clinical research sites Contracted for eight clinical trials Granted DEA Schedule 1 licenses for psilocybin researc...
News, Short Squeeze, Breakout and More Instantly...
The pressure is ramping up on the U.S. Drug Enforcement Administration (DEA) as more lawyers, clinicians, researchers, investors and business owners working in the psychedelics industry are demanding clear answers about how the DEA should be evolving on its drug scheduling and e...
TORONTO, ON / ACCESSWIRE / June 10, 2022 / Novamind Inc. (CSE:NM)(OTCQB:NVMDF)(FSE:HN2) ("Novamind" or the "Company"), a leading mental health company specialized in psychedelic medicine, announced today that the Company has completed its previously announced acquisition by Numinus Welln...
Not for distribution to U.S. Newswire Services or for dissemination in the United States. Any failure to comply with this restriction may constitute a violation of U.S. Securities laws. Numinus shareholders, at a separate meeting held today, have also approved the resolutions related t...